Gain Therapeutics Inc (NASDAQ: GANX) kicked off on Friday, up 11.36% from the previous trading day, before settling in for the closing price of $1.76. Over the past 52 weeks, GANX has traded in a range of $1.41-$2.81.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -37.02%. While this was happening, its average annual earnings per share was recorded 22.89%. With a float of $34.18 million, this company’s outstanding shares have now reached $35.95 million.
The extent of productivity of a business whose workforce counts for 25 workers is very important to gauge.
Gain Therapeutics Inc (GANX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Gain Therapeutics Inc is 4.90%, while institutional ownership is 10.58%.
Gain Therapeutics Inc (GANX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.17 earnings per share (EPS), higher than consensus estimate (set at -0.21) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.74% during the next five years compared to -37.02% drop over the previous five years of trading.
Gain Therapeutics Inc (NASDAQ: GANX) Trading Performance Indicators
Take a look at Gain Therapeutics Inc’s (GANX) current performance indicators. Last quarter, stock had a quick ratio of 1.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Gain Therapeutics Inc (GANX)
The latest stats from [Gain Therapeutics Inc, GANX] show that its last 5-days average volume of 0.64 million was superior to 0.39 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 28.07%.
During the past 100 days, Gain Therapeutics Inc’s (GANX) raw stochastic average was set at 55.56%, which indicates a significant decrease from 57.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1561 in the past 14 days, which was higher than the 0.1502 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8532, while its 200-day Moving Average is $1.8993. Now, the first resistance to watch is $2.0350. This is followed by the second major resistance level at $2.1100. The third major resistance level sits at $2.2400. If the price goes on to break the first support level at $1.8300, it is likely to go to the next support level at $1.7000. The third support level lies at $1.6250 if the price breaches the second support level.
Gain Therapeutics Inc (NASDAQ: GANX) Key Stats
The company with the Market Capitalisation of 70.46 million has total of 35,949K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -20,410 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -5,810 K.
